Browse by Medical Category
Research at Mass General
Nicholas Dyson, PhDProfessor of Medicine; Mary B. Saltonstall Chair in Oncology Harvard Medical School
Scientific DirectorMass General Cancer CenterGeneticistCenter for Cancer ResearchJames and Shirley Curvey MGH Research Scholar
The Dyson Laboratory studies the role of the retinoblastoma tumor suppressor (pRB). pRB is expressed in most cell types and its functions enable cells to stop dividing. pRB is inactivated in many types of cancer; a change that is thought to be an important step in tumor progression. We have three main goals: we want to understand the molecular details of how pRB acts, we want to know how the inactivation of pRB changes the cell, and we are using these insights to target tumor cells.
Nicholas Dyson, PhDPrincipal Investigator
My laboratory investigates mechanisms that limit cell proliferation in normal cells and the ways that these controls are eroded in cancer cells. Our research focuses on the protein product of the retinoblastoma susceptibility gene (RB1) and its target, the E2F transcription factor. E2F controls the expression of a large number of target genes that are needed for cell proliferation. This transcriptional program is activated when normal cells are instructed to divide, but it is deregulated in tumor cells, providing a cellular environment that is permissive for uncontrolled proliferation. pRB has multiple activities but one of its most important roles is to limit the transcription of E2F targets. As a result, most tumor cells select for changes that compromise pRB function. Our research program spans four different aspects of pRB/E2F biology.
Dissecting the molecular functions of pRB
pRB’s mechanism of action is an enigma. pRB has been linked to hundreds of proteins and implicated in many cellular processes. Puriﬁcation of endogenous pRB complexes has been a major challenge and, consequently, it has been unclear which proteins are targeted by pRB at any given moment. Recently, we solved this problem and in collaboration with the Haas lab are using Mass Spectrometry to take detailed snapshots of pRB in action.
Proteomic proﬁles give a new perspective on the effects of RB1 mutation
E2F activity is typically measured by quantifying levels of RNA transcripts synthesized from genes that are controlled by E2F complexes. pRB inactivation changes the transcription of a vast number of genes and it has not been feasible to ask whether these transcriptional events impact protein levels. For over two decades it has been assumed that the RNA changes in RB1 mutant cells are generally followed by similar changes in protein synthesis, and that the RNA signatures give a meaningful picture of a RB1 mutant cell. To test this we generated RNA and protein proﬁles of tissues shortly after ablation of mouse Rb1. Remarkably, we discovered that the two types of data give strikingly different answers. Interestingly, mutation of Rb1 has effects on protein levels that are far more extensive and very different from the changes predicted by RNA data. Unexpectedly, the most consistent proteomic change in Rb1 mutant tissues was a decrease in mitochondrial proteins. Accordingly, RB1 mutant cells have a proliferation disadvantage when grown in low-glucose conditions that put extra demands on mitochondrial function. In such conditions, pRB-deﬁcient cells are more sensitive to mitochondrial poisons. These results reveal that the mutation of Rb1/RB1 changes the cell in ways that had not previously been suspected. The protein signatures may provide useful biomarkers in tumor samples and may reveal new ways to target tumor cells.
Targeting tumor cells with RB1 mutations.
A long-term goal is to use information gleaned from molecular and mechanistic studies to improve cancer treatment. pRB is functionally compromised in most types of cancer but mutation of the RB1 gene is a hallmark event in three types of tumor: retinoblastoma, osteosarcoma and small cell lung cancer (SCLC), suggesting that the complete elimination of pRB activity is especially signiﬁcant in these forms of cancer. In collaboration with Dr. Anna Farago, Jeff Engelman and members of the Haber/Maheswaran laboratories we have generated patient derived xenograft models of SCLC and are testing ways to target these RB1-mutant tumors.
The biological consequences of eliminating E2F activity.
Inhibition of E2F activity has been widely discussed as a potential therapeutic strategy for RB1 mutant tumors. To understand the consequences of global E2F inhibitors we have taken advantage of the relative simplicity of the Drosophila E2F/RB network and have performed a detailed analysis of dDP mutant animals. These mutants completely lack E2F function and, as expected, display extensive transcriptional changes. Proteomic proﬁles of dDP mutant animals reveal changes in protein levels that are different from, and even more extensive than, the transcriptional events. By integrating these RNA and protein proﬁles with ChIP data, we have identiﬁed a set of direct dE2F/dDP target genes are strongly altered in dDP mutant tissues. A genetic screen of these candidates has revealed, unexpectedly, that the upregulation of ATM expression is critical for dDP mutant phenotypes.
A post-doctoral position is available immediately in the laboratory of Nick Dyson at the Massachusetts General Hospital Cancer Center in Boston, Massachusetts. The laboratory is affiliated with Harvard Medical School and is a member of the Dana-Farber/Harvard Cancer Center.
The Dyson laboratory investigates the function of pRB, the protein product of the retinoblastoma tumor susceptibility gene. The RB gene is mutated in wide variety of human cancers. The objective of our research is to understand the molecular and cellular functions of pRB, with the long-term goal to find strategies to target RB mutant tumors. A list of publications can be found via the Cancer Center website at http://www.massgeneral.org/cancerresearch/ourinvestigators/
We are seeking a highly motivated and creative post-doctoral scientist with a successful track record in academic research. Previous experience in studies of protein function and cancer biology is preferred. This project will focus on the analysis of recently discovered proteomic and metabolic signatures of pRB inactivation. These profiles reveal that there are extensive changes in RB-mutant cells and the challenge is to understand why the changes occur, and how they can be exploited.
Applications can be submitted by e-mail to Nick Dyson c/o DysonPostdocSearch@mgh.harvard.edu and should include a one-page cover letter, CV, and contact information of three referees.
View a list of publications by researchers at the Dyson Laboratory
Dyson NJ. RB1: a prototype tumor suppressor and an enigma. Genes and Development, 30(13):1492-502. 2016.
Miles WO, Lembo A, Volorio A, Brachtel E, Tian B, Sgroi D, Provero P and Dyson NJ. Alternative polyadenylation in triple-negative breast tumors allows NRAS and c-JUN to bypass PUMILIO post-transcriptional regulation. Cancer Research, in press. 2016.
Nicolay BN, Danielian PS, Kottakis F, Lapek JD, Sanidas I, Miles WO, Dehnad M, Tschop K, Gierut J, Manning AL, Morris R, Haigis K, Bardeesy N, Lees JA, Haas W, and Dyson NJ (2015). Proteomic analysis of pRb loss highlights a signature of decreased mitochondrial oxidative phosphorylation. Genes and Development 29(17):1875-89. 2015.
Miles WO, Korenjak M, Griffiths LM, Dyer MA, Provero P, Dyson NJ. Post-transcriptional gene expression control by NANOS is up-regulated and functionally important in pRb-deﬁcient cells. EMBO J. 33(19):2201-15. 2014
Korenjak M, Kwon E, Morris RT, Anderssen E, Amzallag A, Ramaswamy S, Dyson NJ. dREAM co-operates with insulator-binding proteins and regulates expression at divergently paired genes. Nucleic Acids Res. 42(14):8939-53. 2014
Manning AL, Yazinski SA, Nicolay B, Bryll A, Zou L, Dyson NJ. Suppression of Genome Instability in pRB-Deﬁcient Cells by Enhancement of Chromosome Cohesion. Molecular Cell. 53(6):993-1004. 2014.
Back to Top